Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 327950, 11 pages
http://dx.doi.org/10.1155/2014/327950
Review Article

Next Generation Delivery System for Proteins and Genes of Therapeutic Purpose: Why and How?

1Institute for Skeletal Aging & Orthopedic Surgery, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon 200704, Republic of Korea
2Department of Physics, School of Basic and Applied Sciences, Galgotias University, Greater Noida 203201, India
3Medical Biotechnology Division, School of Biosciences and Technology, VIT University, Vellore, Tamil Nadu 632014, India
4Department of Bioinformatics, School of Computer Sciences, Galgotias University, Greater Noida 203201, India

Received 28 February 2014; Accepted 9 April 2014; Published 15 July 2014

Academic Editor: Surendra Nimesh

Copyright © 2014 Ashish Ranjan Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Leader, Q. J. Baca, and D. E. Golan, “Protein therapeutics: a summary and pharmacological classification,” Nature Reviews Drug Discovery, vol. 7, no. 1, pp. 21–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Chakraborty and R. Jhingan, Protein Based Drugs: Techno Commercial Approach, Biotech Books, New Delhi, India, 2005.
  3. F. G. Banting, C. H. Best, J. B. Collip, W. R. Campbell, and A. A. Fletcher, “Pancreatic extracts in the treatment of diabetes mellitus: preliminary report 1922,” Canadian Medical Association Journal, vol. 145, no. 10, pp. 1281–1286, 1991. View at Google Scholar · View at Scopus
  4. J. Pickup, “Human insulin,” British Medical Journal, vol. 292, no. 6514, pp. 155–157, 1986. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Schernthaner, “Immunogenicity and allergenic potential of animal and human insulins,” Diabetes Care, vol. 16, no. 3, pp. 155–165, 1993. View at Google Scholar · View at Scopus
  6. D. V. Goeddel, D. G. Kleid, and F. Bolivar, “Expression in Escherichia coli of chemically synthesized genes for human insulin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 1, pp. 106–110, 1979. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Keen, A. Glynne, and J. C. Pickup, “Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men,” The Lancet, vol. 2, no. 8191, pp. 398–401, 1980. View at Google Scholar · View at Scopus
  8. A. J. L. Clark, R. O. Adeniyi-Jones, G. Knight et al., “Biosynthetic human insulin in the treatment of diabetes,” The Lancet, vol. 2, no. 8294, pp. 354–357, 1982. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Chakraborty, Production Technology of Recombinant Therapeutic Proteins, Biotech Books, New Delhi, India, 2004.
  10. G. Walsh, “Biopharmaceutical benchmarks 2010,” Nature Biotechnology, vol. 28, no. 9, pp. 917–924, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Chakraborty and G. Agoramoorthy, “A special report on India's biotech scenario: advancement in biopharmaceutical and health care sectors,” Biotechnology Advances, vol. 28, no. 1, pp. 1–6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Friedmann and R. Roblin, “Gene therapy for human genetic disease?” Science, vol. 175, no. 4025, pp. 949–955, 1972. View at Publisher · View at Google Scholar · View at Scopus
  13. M. L. Edelstein, M. R. Abedi, and J. Wixon, “Gene therapy clinical trials worldwide to 2007—an update,” Journal of Gene Medicine, vol. 9, no. 10, pp. 833–842, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. S. L. Ginn, I. E. Alexander, M. L. Edelstein, M. R. Abedi, and J. Wixon, “Gene therapy clinical trials worldwide to 2012—an update,” Journal of Gene Medicine, vol. 15, no. 2, pp. 65–77, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Kayser and H. Warzecha, Eds., Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications, John Wiley & Sons, 2012.
  16. T. M. Allen and P. R. Cullis, “Drug delivery systems: entering the mainstream,” Science, vol. 303, no. 5665, pp. 1818–1822, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Chakraborty, S. Pal, G. P. Doss, Z. Wen, and C. Lin, “Nanoparticles as “smart” pharmaceutical delivery,” Frontiers in Bioscience, vol. 18, no. 3, pp. 1030–1050, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Fletcher, “Drug delivery: strategies and technologies,” Pharmaceutical Science & Technology Today, vol. 1, no. 2, pp. 49–51, 1998. View at Google Scholar
  19. A. T. Florence, “New drug delivery systems,” Chemistry and Industry, no. 24, pp. 1000–1004, 1993. View at Google Scholar · View at Scopus
  20. R. Langer, “New methods of drug delivery,” Science, vol. 249, no. 4976, pp. 1527–1533, 1990. View at Publisher · View at Google Scholar · View at Scopus
  21. R. K. Verma and S. Garg, “Current status of drug delivery technologies and future directions,” Pharmaceutical Technology, vol. 25, no. 2, pp. 1–14, 2001. View at Google Scholar
  22. L. R. Brown, “Commercial challenges of protein drug delivery,” Expert Opinion on Drug Delivery, vol. 2, no. 1, pp. 29–42, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Reichert, “Trends in development and approval times for new therapeutics in the United States,” Nature Reviews Drug Discovery, vol. 2, no. 9, pp. 695–702, 2003. View at Google Scholar · View at Scopus
  24. Y. Seow and M. J. Wood, “Biological gene delivery vehicles: beyond viral vectors,” Molecular Therapy, vol. 17, no. 5, pp. 767–777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. D. S. Dimitrov, “Therapeutic proteins,” Methods in Molecular Biology, vol. 899, pp. 1–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. D. S. Pisal, M. P. Kosloski, and S. V. Balu-Iyer, “Delivery of therapeutic proteins,” Journal of Pharmaceutical Sciences, vol. 99, no. 6, pp. 2557–2575, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Kay, “State-of-the-art gene-based therapies: the road ahead,” Nature Reviews Genetics, vol. 12, no. 5, pp. 316–328, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. D. B. Kohn, “Update on gene therapy for immunodeficiencies,” Clinical Immunology, vol. 135, no. 2, pp. 247–254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Depreter, G. Pilcer, and K. Amighi, “Inhaled proteins: challenges and perspectives,” International Journal of Pharmaceutics, vol. 447, no. 1-2, pp. 251–280, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Zhang, K. F. Chan, R. Haryadi, M. Bardor, and Z. Song, “CHO glycosylation mutants as potential host cells to produce therapeutic proteins with enhanced efficacy,” Advances in Biochemical Engineering/Biotechnology, vol. 131, pp. 63–87, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Gregoriadis, S. Jain, I. Papaioannou, and ETAL, “Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids,” International Journal of Pharmaceutics, vol. 300, no. 1-2, pp. 125–130, 2005. View at Publisher · View at Google Scholar
  32. U. V. Banakar, “Advances and opportunities in delivery of therapeutic proteins and peptides,” Journal of Biomaterials Applications, vol. 11, no. 4, pp. 377–429, 1997. View at Google Scholar · View at Scopus
  33. Y. Levy, M. S. Hershfield, C. Fernandez-Mejia et al., “Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase,” Journal of Pediatrics, vol. 113, no. 2, pp. 312–317, 1988. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Coura Rdos and N. B. Nardi, “The state of the art of adeno-associated virus based vectors in gene therapy,” Virology Journal, vol. 7, article 12, 2007. View at Google Scholar
  35. S. Hacein-Bey-Abina, A. Garrigue, G. P. Wang et al., “Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1,” Journal of Clinical Investigation, vol. 118, no. 9, pp. 3132–3142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Kedika and S. V. Patri, “Benzothiazole head group based cationic lipids: synthesis and application for gene delivery,” European Journal of Medicinal Chemistry, vol. 74, pp. 703–716, 2013. View at Publisher · View at Google Scholar
  37. J. Sánchez-Nieves, P. Fransen, D. Pulido et al., “Amphiphilic cationic carbosilane–PEG dendrimers: synthesis and applications in gene therapy,” European Journal of Medicinal Chemistry, vol. 76, pp. 43–52, 2014. View at Google Scholar
  38. J. Swaminathan and C. Ehrhardt, “Liposomal delivery of proteins and peptides,” Expert Opinion on Drug Delivery, vol. 9, no. 12, pp. 1489–1503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. H. M. Patel and B. E. Ryman, “Oral administration of insulin by encapsulation within liposomes,” The FEBS Letters, vol. 62, no. 1, pp. 60–63, 1976. View at Publisher · View at Google Scholar · View at Scopus
  40. H. M. Patel, R. W. Stevenson, J. A. Parsons, and B. E. Ryman, “Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs,” Biochimica et Biophysica Acta, vol. 716, no. 2, pp. 188–193, 1982. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Chiang and N. Weiner, “Gastrointestinal uptake of liposomes. II. In vivo studies,” International Journal of Pharmaceutics, vol. 40, no. 1-2, pp. 143–150, 1987. View at Publisher · View at Google Scholar · View at Scopus
  42. A. D. Bangham, M. M. Standish, and J. C. Watkins, “Diffusion of univalent ions across the lamellae of swollen phospholipids,” Journal of Molecular Biology, vol. 13, no. 1, pp. 238–252, 1965. View at Google Scholar · View at Scopus
  43. L. D. Mayer, P. R. Cullis, and M. B. Bally, “The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin,” Journal of Liposome Research, vol. 4, no. 1, pp. 529–553, 1994. View at Google Scholar · View at Scopus
  44. D. D. Lasic, “Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo,” Journal of Controlled Release, vol. 48, no. 2-3, pp. 203–222, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. A. S. Ulrich, “Biophysical aspects of using liposomes as delivery vehicles,” Bioscience Reports, vol. 22, no. 2, pp. 129–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Gregoriadis, Liposomes as Drug Carriers. Recent Trend and Progress, John Wiley & Sons, New York, NY, USA, 1988.
  47. M. L. Immordino, F. Dosio, and L. Cattel, “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential,” International Journal of Nanomedicine, vol. 1, no. 3, pp. 297–315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. R. M. Abra, R. B. Bankert, F. Chen et al., “The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients,” Journal of Liposome Research, vol. 12, no. 1-2, pp. 1–3, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Cattel, M. Ceruti, and F. Dosio, “From conventional to stealth liposomes: a new frontier in cancer chemotherapy,” Journal of Chemotherapy, vol. 16, no. 4, pp. 94–97, 2004. View at Google Scholar · View at Scopus
  50. P. A. Dinndorf, J. Gootenberg, M. H. Cohen, P. Keegan, and R. Pazdur, “FDA drug approval summary: pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL),” Oncologist, vol. 12, no. 8, pp. 991–998, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. R. M. Bukowski, C. Tendler, D. Cutler, E. Rose, M. M. Laughlin, and P. Statkevich, “Treating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation,” Cancer, vol. 95, no. 2, pp. 389–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. M. W. Fried, M. L. Shiffman, R. K. Reddy et al., “Pegylated (40kDa) interferon alfa-2a (in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study,” Gastroenterology, vol. 120, no. 5, article A55, 2001. View at Google Scholar
  53. G. Molineux, “The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta),” Current Pharmaceutical Design, vol. 10, no. 11, pp. 1235–1244, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. I. C. Macdougall and K. U. Eckardt, “Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia,” The Lancet, vol. 368, no. 9539, pp. 947–953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Haussecker, “The business of RNAi therapeutics in 2012,” Molecular Therapy-Nucleic Acids, vol. 7, no. 1, article e8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Büning, “Gene therapy enters the pharma market: the short story of a long journey,” EMBO Molecular Medicine, vol. 5, no. 1, pp. 1–3, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. O. G. Mouritsen and K. Jørgensen, “A new look at lipid-membrane structure in relation to drug research,” Pharmaceutical Research, vol. 15, no. 10, pp. 1507–1519, 1998. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Langner and T. E. Kral, “Liposome-based drug delivery systems,” Polish Journal of Pharmacology, vol. 51, no. 3, pp. 211–222, 1999. View at Google Scholar · View at Scopus
  59. M. Langner, “Effect of liposome molecular composition on its ability to carry drugs,” Polish Journal of Pharmacology, vol. 52, no. 1, pp. 3–14, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. D. C. Drummond, M. Zignani, and J. Leroux, “Current status of pH-sensitive liposomes in drug delivery,” Progress in Lipid Research, vol. 39, no. 5, pp. 409–460, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. I. M. Hafez and P. R. Cullis, “Roles of lipid polymorphism in intracellular delivery,” Advanced Drug Delivery Reviews, vol. 47, no. 2-3, pp. 139–148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. R. New, Liposomes—A Practical Approach, vol. 58, IRL Press at Oxford University Press, 1994.
  63. R. B. Gennis, Biomembranes: Molecular Structure and Function, Springer, 1989, edited by C. Cantor.
  64. K. Ramani, R. D. Miclea, V. S. Purohit, D. E. Mager, R. M. Straubinger, and S. V. Balu-Iyer, “Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A,” Journal of Pharmaceutical Sciences, vol. 97, no. 4, pp. 1386–1398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos, “Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors,” Pharmacological Reviews, vol. 51, no. 4, pp. 691–744, 1999. View at Google Scholar · View at Scopus
  66. V. P. Torchilin and V. S. Trubetskoy, “Which polymers can make nanoparticulate drug carriers long-circulating?” Advanced Drug Delivery Reviews, vol. 16, no. 2-3, pp. 141–155, 1995. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Maeda, T. Sawa, and T. Konno, “Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS,” Journal of Controlled Release, vol. 74, no. 1–3, pp. 47–61, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Mastrobattista, G. A. Koning, L. Van Bloois, A. C. S. Filipe, W. Jiskoot, and G. Storm, “Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins,” Journal of Biological Chemistry, vol. 277, no. 30, pp. 27135–27143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Bendas, A. Krause, R. Schmidt, and J. Vogel, “Selectins as new targets for immunoliposome-mediated drug delivery: a potential way of anti-inflammatory therapy,” Pharmaceutica Acta Helvetiae, vol. 73, no. 1, pp. 19–26, 1998. View at Publisher · View at Google Scholar · View at Scopus
  70. S. M. Moghimi and J. Szebeni, “Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties,” Progress in Lipid Research, vol. 42, no. 6, pp. 463–478, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Maruyama, T. Takizawa, N. Takahashi, T. Tagawa, K. Nagaike, and M. Iwatsuru, “Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals,” Advanced Drug Delivery Reviews, vol. 24, no. 2-3, pp. 235–242, 1997. View at Publisher · View at Google Scholar · View at Scopus
  72. V. P. Torchilin, “Recent advances with liposomes as pharmaceutical carriers,” Nature Reviews Drug Discovery, vol. 4, no. 2, pp. 145–160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. A. A. Gabizon, “Liposome circulation time and tumor targeting: implications for cancer chemotherapy,” Advanced Drug Delivery Reviews, vol. 16, no. 2-3, pp. 285–294, 1995. View at Publisher · View at Google Scholar · View at Scopus
  74. I. Matsuda, H. Konno, T. Tanaka, and S. Nakamura, “Antimetastatic effect of hepatotropic liposomal adriamycin on human metastatic liver tumors,” Surgery Today, vol. 31, no. 5, pp. 414–420, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Hashida, M. Nishikawa, F. Yamashita, and Y. Takakura, “Cell-specific delivery of genes with glycosylated carriers,” Advanced Drug Delivery Reviews, vol. 52, no. 3, pp. 187–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. J. H. Felgner, R. Kumar, C. N. Sridhar et al., “Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations,” Journal of Biological Chemistry, vol. 269, no. 4, pp. 2550–2561, 1994. View at Google Scholar · View at Scopus
  77. H. Farhood, N. Serbina, and L. Huang, “The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer,” Biochimica et Biophysica Acta: Biomembranes, vol. 1235, no. 2, pp. 289–295, 1995. View at Publisher · View at Google Scholar · View at Scopus
  78. D. B. Stanimirovic, M. Markovic, D. V. Micic, M. Spatz, and B. B. Mrsulja, “Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion 'oxidative stress' in gerbil brain,” Neurochemical Research, vol. 19, no. 12, pp. 1473–1478, 1994. View at Publisher · View at Google Scholar · View at Scopus
  79. M. E. M. Cruz, M. M. Gaspar, M. B. F. Martins, and M. L. Corvo, “Liposomal superoxide dismutases and their use in the treatment of experimental arthritis,” Methods in Enzymology, vol. 391, pp. 395–413, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. Lo, J. Tsai, and J. Kuo, “Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase,” Journal of Controlled Release, vol. 94, no. 2-3, pp. 259–272, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. V. P. Torchilin, Immobilized Enzymes in Medicine, Springer, Berlin, Germany, 1991.
  82. M. M. Gaspar, R. Perez-Soler, and M. E. M. Cruz, “Biological characterization of L-asparginase liposomal formulations,” Cancer Chemotherapy & Pharmacology, vol. 38, no. 4, pp. 373–377, 1996. View at Publisher · View at Google Scholar · View at Scopus
  83. J. L. M. Heeremans, R. Prevost, M. E. A. Bekkers et al., “Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA,” Thrombosis and Haemostasis, vol. 73, no. 3, pp. 488–494, 1995. View at Google Scholar · View at Scopus
  84. M. H. Vingerhoeds, H. J. Haisma, S. O. Belliot, R. H. P. Smit, D. J. A. Crommelin, and G. Storm, “Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity,” Pharmaceutical Research, vol. 13, no. 4, pp. 604–610, 1996. View at Publisher · View at Google Scholar · View at Scopus
  85. M. J. Fonseca, J. C. Jagtenberg, H. J. Haisma, and G. Storm, “Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: Comparison with the corresponding antibody-enzyme conjugate,” Pharmaceutical Research, vol. 20, no. 3, pp. 423–428, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. K. W. C. Mok and P. R. Cullis, “Structural and fusogenic properties of cationic liposomes in the presence of plasmid DNA,” Biophysical Journal, vol. 73, no. 5, pp. 2534–2545, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Hirko, F. Tang, and J. A. Hughes, “Cationic lipid vectors for plasmid DNA delivery,” Current Medicinal Chemistry, vol. 10, no. 14, pp. 1185–1193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. B. Martin, M. Sainlos, A. Aissaoui et al., “The design of cationic lipids for gene delivery,” Current Pharmaceutical Design, vol. 11, no. 3, pp. 375–394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Lappalainen, I. Jääskeläinen, K. Syrjänen et al., “Comparison of cell proliferation and toxicity assays using two cationic liposomes,” Pharmaceutical Research, vol. 11, no. 8, pp. 1127–1131, 1994. View at Google Scholar
  90. M. C. Filion and N. C. Phillips, “Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells,” Biochimica et Biophysica Acta: Biomembranes, vol. 1329, no. 2, pp. 345–356, 1997. View at Publisher · View at Google Scholar · View at Scopus
  91. P. L. Felgner, T. R. Gadek, M. Holm et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7413–7417, 1987. View at Publisher · View at Google Scholar · View at Scopus
  92. D. C. Litzinger, J. M. Brown, I. Wala et al., “Fate of cationic liposomes and their complex with oligonucleotide in vivo,” Biochimica et Biophysica Acta—Biomembranes, vol. 1281, no. 2, pp. 139–149, 1996. View at Publisher · View at Google Scholar · View at Scopus
  93. D. D. Stuart and T. M. Allen, “A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability,” Biochimica et Biophysica Acta—Biomembranes, vol. 1463, no. 2, pp. 219–229, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. N. Maurer, A. Mori, L. Palmer et al., “Lipid-based systems for the intracellular delivery of genetic drugs,” Molecular Membrane Biology, vol. 16, no. 1, pp. 129–140, 1999. View at Publisher · View at Google Scholar · View at Scopus
  95. S. C. Semple, S. K. Klimuk, T. O. Harasym et al., “Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures,” Biochimica et Biophysica Acta: Biomembranes, vol. 1510, no. 1-2, pp. 152–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Maurer, K. F. Wong, H. Stark et al., “Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes,” Biophysical Journal, vol. 80, no. 5, pp. 2310–2326, 2001. View at Publisher · View at Google Scholar · View at Scopus
  97. S. C. Semple, A. Akinc, J. Chen et al., “Rational design of cationic lipids for siRNA delivery,” Nature Biotechnology, vol. 28, no. 2, pp. 172–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. D. D. Stuart, G. Y. Kao, and T. M. Allen, “A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1,” Cancer Gene Therapy, vol. 7, no. 3, pp. 466–475, 2000. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Akinc, W. Querbes, S. De et al., “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms,” Molecular Therapy, vol. 18, no. 7, pp. 1357–1364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Basha, T. I. Novobrantseva, N. Rosin et al., “Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells,” Molecular Therapy, vol. 19, no. 12, pp. 2186–2200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Jayaraman, S. M. Ansell, B. L. Mui et al., “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo,” Angewandte Chemie—International Edition, vol. 51, no. 34, pp. 8529–8533, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Milton Harris and R. B. Chess, “Effect of pegylation on pharmaceuticals,” Nature Reviews Drug Discovery, vol. 2, no. 3, pp. 214–221, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. G. Pasut and F. M. Veronese, “State of the art in PEGylation: the great versatility achieved after forty years of research,” Journal of Controlled Release, vol. 161, no. 2, pp. 461–472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Jevševar, M. Kunstelj, and V. G. Porekar, “PEGylation of therapeutic proteins,” Biotechnology Journal, vol. 5, no. 1, pp. 113–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. J. González-Valdez, M. Rito-Palomares, and J. Benavides, “Advances and trends in the design, analysis, and characterization of polymer-protein conjugates for “pEGylaided” bioprocesses,” Analytical and Bioanalytical Chemistry, vol. 403, no. 8, pp. 2225–2235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. M. S. Hershfield, “PEG-ADA replacement therapy for adenosine deaminase deficiency: an update alter 8.5 years,” Clinical Immunology and Immunopathology, vol. 76, no. 3, part 2, pp. S228–S232, 1995. View at Publisher · View at Google Scholar · View at Scopus
  107. K. L. Lindsay, C. Trepo, T. Heintges et al., “A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C,” Hepatology, vol. 34, no. 2, pp. 395–403, 2001. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Yamamoto, Y. Tsutsumi, Y. Yoshioka et al., “Site-specific pegylation of a lysine-deficient TNF-α with full bioactivity,” Nature Biotechnology, vol. 21, no. 5, pp. 546–552, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. R. M. Blaese, K. W. Culver, A. D. Miller et al., “T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years,” Science, vol. 270, no. 5235, pp. 475–480, 1995. View at Publisher · View at Google Scholar · View at Scopus
  110. S. J. Howe, M. R. Mansour, K. Schwarzwaelder et al., “Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients,” Journal of Clinical Investigation, vol. 118, no. 9, pp. 3143–3150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. F. Ferrua, I. Brigida, and A. Aiuti, “Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency,” Current Opinion in Allergy and Clinical Immunology, vol. 10, no. 6, pp. 551–556, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. H. B. Gaspar, A. Aiuti, F. Porta, F. Candotti, M. S. Hershfield, and L. D. Notarangelo, “How I treat ADA deficiency,” Blood, vol. 114, no. 17, pp. 3524–3532, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Aiuti, F. Cattaneo, S. Galimberti et al., “Gene therapy for immunodeficiency due to adenosine deaminase deficiency,” The New England Journal of Medicine, vol. 360, no. 5, pp. 447–458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Ogino, M. L. Gulley, J. T. den Dunnen et al., “Standard mutation nomeclature in molecular diagnostics: practical and educational challenges,” Journal of Molecular Diagnostics, vol. 9, no. 1, pp. 1–6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. H. B. Gaspar, “Bone marrow transplantation and alternatives for adenosine deaminase deficiency,” Immunology and Allergy Clinics of North America, vol. 30, no. 2, pp. 221–236, 2010. View at Google Scholar
  116. H. Schellekens, W. E. Hennink, and V. Brinks, “The immunogenicity of polyethylene glycol: facts and fiction,” Pharmaceutical Research, vol. 30, no. 7, pp. 1729–1734, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Noga, D. Edinger, R. Kläger et al., “The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes,” Biomaterials, vol. 34, no. 10, pp. 2530–2538, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Besheer, G. Hause, J. Kressler, and K. Mäder, “Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles,” Biomacromolecules, vol. 8, no. 2, pp. 359–367, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. GMBH FKD, “Hesylation Technology; AAPS National Biotechnology Conference,” Toronto, Canada, abstract, 2008.
  120. A. O. Elzoghby, W. M. Samy, and N. A. Elgindy, “Albumin-based nanoparticles as potential controlled release drug delivery systems,” Journal of Controlled Release, vol. 157, no. 2, pp. 168–182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. E. J. Lee, S. A. Khan, J. K. Park, and K. Lim, “Studies on the characteristics of drug-loaded gelatin nanoparticles prepared by nanoprecipitation,” Bioprocess and Biosystems Engineering, vol. 35, no. 1-2, pp. 297–307, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. T. Mirshahi, J. M. Irache, C. Nicolas et al., “Adaptive immune responses of legumin nanoparticles,” Journal of Drug Targeting, vol. 10, no. 8, pp. 625–631, 2002. View at Publisher · View at Google Scholar · View at Scopus
  123. L. Vincent, J. Varet, J. Pille et al., “Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: In vitro and in vivo studies,” International Journal of Cancer, vol. 105, no. 3, pp. 419–429, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. C. H. Ahn, S. Y. Chae, Y. H. Bae, and S. W. Kim, “Biodegradable poly(ethylenimine) for plasmid DNA delivery,” Journal of Controlled Release, vol. 80, no. 1–3, pp. 273–282, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. G. F. Paciotti, L. Myer, D. Weinreich et al., “Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery,” Drug Delivery, vol. 11, no. 3, pp. 169–183, 2004. View at Publisher · View at Google Scholar · View at Scopus
  126. G. Kaul and M. Amiji, “Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in Vivo studies,” Pharmaceutical Research, vol. 22, no. 6, pp. 951–961, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. W. Tan, K. Wang, X. He et al., “Bionanotechnology based on silica nanoparticles,” Medicinal Research Reviews, vol. 24, no. 5, pp. 621–638, 2004. View at Publisher · View at Google Scholar · View at Scopus
  128. C. Kneuer, M. Sameti, U. Bakowsky et al., “A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro,” Bioconjugate Chemistry, vol. 11, no. 6, pp. 926–932, 2000. View at Publisher · View at Google Scholar · View at Scopus
  129. C. Kneuer, M. Sameti, E. G. Haltner et al., “Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA,” International Journal of Pharmaceutics, vol. 196, no. 2, pp. 257–261, 2000. View at Publisher · View at Google Scholar · View at Scopus
  130. N. Singh, M. Briones, G. Ott, and D. O'Hagan, “Cationic microparticles: a potent delivery system for DNA vaccines,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 811–816, 2000. View at Publisher · View at Google Scholar
  131. M. Junghans, J. Kreuter, and A. Zimmer, “Antisense delivery using protamine-oligonucleotide particles,” Nucleic Acids Research, vol. 28, article E45, no. 10, 2000. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Méndez-Ardoy, K. Urbiola, C. Aranda, C. Ortiz-Mellet, J. M. Garca-Fernndez, and C. Tros de Ilarduya, “Polycationic amphiphilic cyclodextrin-based nanoparticles for therapeutic gene delivery,” Nanomedicine, vol. 6, no. 10, pp. 1697–1707, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Beloor, C. S. Choi, H. Y. Nam et al., “Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA,” Biomaterials, vol. 33, no. 5, pp. 1640–1650, 2012. View at Publisher · View at Google Scholar · View at Scopus